Paratek publishes positive PhIII data on approved Nuzyra; Allergan settles opioid lawsuits in two Ohio counties
→ Paratek Pharmaceuticals‘ $PRTK Nuzyra (omadacycline) has met all primary and secondary clinical study endpoints in their OASIS-2 Phase III clinical trial, according to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.